To The Moon

After-Hours Stock Movers:

Coupa Software (NASDAQ: COUP) 27.5% LOWER; reported Q4 EPS of $0.19, $0.14 better than the analyst estimate of $0.05. Revenue for the quarter came in at $193.3 million versus the consensus estimate of $185.68 million. Coupa Software sees Q1 2023 EPS of $0.03-$0.06, versus the consensus of $0.05. Coupa Software sees Q1 2023 revenue of $189-191 million, versus the consensus of $196.1 million. Coupa Software sees FY2023 EPS of $0.15-$0.19, versus the consensus of $0.74. Coupa Software sees FY2023 revenue of $836-840 million, versus the consensus of $877.5 million.

GitLab Inc (NASDAQ: GTLB) 9.6% HIGHER; reported Q4 EPS of ($0.16), $0.09 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $77.8 million versus the consensus estimate of $70.29 million. GitLab Inc sees Q1 2023 EPS of ($0.28)-($0.27), versus the consensus of ($0.30). GitLab Inc sees Q1 2023 revenue of $77-78 million, versus the consensus of $72.8 million. GitLab Inc sees FY2022 EPS of ($1.02)-($0.97), versus the consensus of ($1.04). GitLab Inc sees FY2022 revenue of $385.5-390.5 million, versus the consensus of $336.64 million.

AnaptysBio, Inc. (Nasdaq: ANAB) 9.5% LOWER; announced that top-line data from its Phase 2 clinical trial of imsidolimab for the treatment of moderate-to-severe acne, also known as the ACORN trial, did not demonstrate efficacy over placebo on primary or secondary endpoints.

Westport Fuel Systems (NASDAQ: WPRT) 2.9% HIGHER; reported Q4 EPS of $0.03, $0.03 better than the analyst estimate of $0.00. Revenue for the quarter came in at $82.7 million versus the consensus estimate of $86.62 million.

Exelixis, Inc. (Nasdaq: EXEL) 3.4% LOWER; announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial, which evaluated cabozantinib (CABOMETYX®) in combination with atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma (HCC). The final analysis showed neither improvement nor detriment in OS for cabozantinib in combination with atezolizumab versus sorafenib. Based on this outcome for OS and the rapidly evolving treatment landscape for previously untreated advanced HCC, Exelixis does not intend to submit a supplemental New Drug Application to the U.S. Food and Drug Administration (FDA). Full results will be presented at a future medical meeting.

CIRCOR International, Inc. (NYSE: CIR) 2.4% LOWER; discovers accounting irregularities, receives takeover interest from multiple parties.

Tilly’s, Inc. (NYSE: TLYS) 1.5% HIGHER; announced today that its Board of Directors has authorized a share repurchase program, pursuant to which the Company may repurchase up to two million shares of the Company’s Class A common stock over the next twelve months through March 14, 2023